Hikma Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	3,216	3,127	2,875	2,517	2,553	2,341
Revenue Growth (YoY)	6.60%	8.77%	14.22%	-1.41%	9.06%	6.07%
Cost of Revenue	1,832	1,712	1,468	1,252	1,252	1,128
Gross Profit	1,384	1,415	1,407	1,265	1,301	1,213
Selling, General & Admin	660	662	632	601	561	506
Research & Development	153	141	149	144	143	137
Other Operating Expenses	-9	4	1	22	36	30
Operating Expenses	804	807	782	767	740	673
Operating Income	580	608	625	498	561	540
Interest Expense	-71	-75	-73	-59	-43	-41
Interest & Investment Income	8	8	7	3	1	7
Earnings From Equity Investments	-	1	-	-	1	-
Currency Exchange Gain (Loss)	-21	-21	-9	-7	-	-
Other Non Operating Income (Expenses)	-13	-13	-14	-11	-13	-11
EBT Excluding Unusual Items	483	508	536	424	507	495
Merger & Restructuring Charges	-21	-9	-	-41	-	-3
Gain (Loss) on Sale of Investments	2	1	2	-2	-	1
Gain (Loss) on Sale of Assets	-	-	-	12	-1	-2
Asset Writedown	29	29	-85	-182	22	33
Legal Settlements	-72	-	-129	-	-	-
Other Unusual Items	27	-74	-43	22	16	23
Pretax Income	462	455	281	233	544	558
Income Tax Expense	89	93	89	42	124	128
Earnings From Continuing Operations	373	362	192	191	420	430
Minority Interest in Earnings	-2	-3	-2	-3	1	1
Net Income	371	359	190	188	421	431
Net Income to Common	371	359	190	188	421	431
Net Income Growth	30.18%	88.95%	1.06%	-55.34%	-2.32%	-11.32%
Shares Outstanding (Basic)	221	221	221	224	231	236
Shares Outstanding (Diluted)	223	223	222	225	233	238
Shares Change (YoY)	-0.18%	0.51%	-1.13%	-3.47%	-2.10%	-2.06%
EPS (Basic)	1.68	1.62	0.86	0.84	1.82	1.83
EPS (Diluted)	1.67	1.61	0.85	0.84	1.81	1.81
EPS Growth	31.16%	89.41%	1.19%	-53.51%	-0.22%	-9.45%
Free Cash Flow	363	399	439	392	493	292
Free Cash Flow Per Share	1.63	1.78	1.97	1.74	2.12	1.23
Dividend Per Share	0.840	0.800	0.720	0.560	0.540	0.500
Dividend Growth	6.33%	11.11%	28.57%	3.70%	8.00%	13.64%
Gross Margin	43.04%	45.25%	48.94%	50.26%	50.96%	51.81%
Operating Margin	18.04%	19.44%	21.74%	19.79%	21.97%	23.07%
Profit Margin	11.54%	11.48%	6.61%	7.47%	16.49%	18.41%
Free Cash Flow Margin	11.29%	12.76%	15.27%	15.57%	19.31%	12.47%
EBITDA	764	787	797	670	718	654
EBITDA Margin	23.76%	25.17%	27.72%	26.62%	28.12%	27.94%
D&A For EBITDA	184	179	172	172	157	114
EBIT	580	608	625	498	561	540
EBIT Margin	18.04%	19.44%	21.74%	19.79%	21.97%	23.07%
Effective Tax Rate	19.26%	20.44%	31.67%	18.03%	22.79%	22.94%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.